Loading
Life sciences · Review
Pharmacological Research · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Neurodegenerative disorders are a leading cause of disability and mortality globally, but effective disease-modifying therapeutic strategies are still largely unavailable. Scutellarin is a flavonoid glycoside extracted from Erigeron breviscapus (Vant.) Hand-Mazz. It has been widely studied in preclinical models of neurodegenerative disorders. In this study, we performed a systematic review of preclinical animal studies. We combined comprehensive database retrieval with quantitative synthesis of eligible outcomes. The pooled results demonstrated that scutellarin significantly reduced cerebral infarct volume and improved neurological deficit scores in cerebral ischemia-reperfusion models. It also ameliorated learning and memory impairments in experimental Alzheimer's disease (AD) models. Consistent neuroprotective effects were also found in models of depression, anxiety, Parkinson's disease, etc. Mechanistic analysis indicated that scutellarin produces multi-level neuroprotective effects. It acts by reducing oxidative stress, inhibiting neuroinflammation, suppressing apoptosis, stabilizing the neurovascular unit and other neurobiological processes. This review first evaluated the preclinical efficacy of scutellarin through systematic review and meta-analysis. It then integrated cross-disease mechanisms with network pharmacology, reverse virtual screening and molecular docking to identify computationally predicted targets. Although scutellarin shows promising preclinical effects, its clinical translation faces major limitations. These limitations include low oral bioavailability, poor blood-brain barrier (BBB) penetration and insufficient data on brain exposure. Overall, scutellarin is a multi-target neuroprotective candidate. Future studies should focus on target validation, exposure-response modeling, delivery optimization and clinically relevant translational evaluation.